Smith & Nephew plc logo

SNN Earnings Date: Feb 23, 2027 (Estimated) — Smith & Nephew plc

NYSE · Healthcare · Medical Devices

Updated

Price $30.41
Market Cap $12.3B
P/E 19.1
52W Range $26.09 – $36.55
Next Earnings · Before open (est.)

When is SNN's next earnings date?

Smith & Nephew plc (SNN) is expected to report FY 2026 earnings on Tuesday, February 23, 2027 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $2.22 on revenue of $6.48B.

How did SNN do in its last earnings report?

In its most recent report on Aug 4, 2026 (H1 2026), Smith & Nephew plc posted EPS of $0.48 versus the $0.94 estimate, a miss of 49.2%. Revenue was $3.10B against a $3.46B estimate. The stock's 1-day post-earnings move was -5.3%.

How much does SNN stock move after earnings?

SNN beat EPS estimates in 1 of its last 4 reported quarters. Over the last 6 reports the stock moved an average of 4.5% (up or down) in the day after earnings.

About Smith & Nephew plc

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Earnings History

DatePeriodEPS Est.EPS Act.SurpriseRevenueResult1D Δ1W Δ1M Δ
2026-08-04H1 20260.940.48-49.20%$3.10B❌ Miss-5.32%-6.45%-9.88%
2026-03-16FY 20251.891.02-46.03%$6.16B❌ Miss+0.40%-3.08%+5.76%
2025-02-25FY 2024—0.84—$5.81B—+6.96%+12.83%+8.20%
2024-08-01H1 2024—0.38—$2.83B—+6.89%+3.32%+7.55%
2024-02-27FY 2023—0.83—$5.55B—-2.01%-7.11%-8.59%
2023-02-21FY 2022—0.82—$5.21B—+5.50%+3.71%+2.87%
2022-07-280.760.76—$2.60B✅ Beat———
2022-02-220.870.80—$2.61B❌ Miss———

Showing last 8 quarters.

Related Companies

Learn More

Explore More

Financial data from licensed market-data providers; risk factors from SEC EDGAR filings. AI-powered analysis. Data last updated .